



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Resiquimod (GMP)

Cat. No.:	HY-13740G
CAS No.:	144875-48-9
Molecular Formula:	C ₁₇ H ₂₂ N ₄ O ₂
Molecular Weight:	314.38
Target:	Toll-like Receptor (TLR)
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages ^{[1][2][3]} .	
IC₅₀ & Target	TLR7	TLR8
In Vitro	Resiquimod (GMP) (3 µg/mL, 5 days) induces human mMDSC to mature into inflammatory macrophage (MAC _{inflam}) ^[1] . Resiquimod (GMP) (3 µg/mL, 3 days) produces IL-6 and IL-12 in human mMDSC ^[1] . Resiquimod (GMP) (2.5 µg/mL, 7 days) transdifferentiates memory B cells to IgG producing plasma cells ^[2] . Resiquimod (GMP) (5 µg/mL, 5 days) induces the differentiation of MDSCs into mature myeloid cells ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

CUSTOMER VALIDATION

- Nat Nanotechnol. 2023 Jan 12.
- Adv Mater. 2022 Nov 25;e2208782.
- Nat Biomed Eng. 2018 Aug;2(8):578-588.
- ACS Nano. 2022 Sep 27;16(9):15226-15236.
- ACS Nano. 2021 Sep 2;acs.nano.1c03252.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bayik D, et al. Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages. *Front Immunol.* 2018 Mar 26;9:608.

[2]. Preisendörfer S, et al. FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. *Cells.* 2022 Apr 14;11(8):1341.

[3]. Lee M, et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37(9):1234-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA